“I think we’re in the early innings of the upswing,” Borisy said. But “we don’t know for sure. Because when you're down in the trough, you can have false dawns, and you can bounce along there for a long period of time.”The tension could be felt throughout J.P. Morgan. There was real frustration when, on the conference’s opening day, no major deals came. Brad Loncar, another prominent biotech investor turned media analyst, lamented the “slowest JPM for news in a long time.” Others appear to agree. The XBI, a ...

Core Insights - SCTbio and Fortrea have announced a strategic collaboration to enhance the development and delivery of advanced therapies, aiming to streamline processes and accelerate timelines for bringing therapies to patients [1][2][3] Company Overview - SCTbio is a leading Contract Development and Manufacturing Organization (CDMO) with over 15 years of experience in GMP manufacturing for Advanced Therapy Medicinal Products (ATMPs), providing end-to-end services including apheresis materials, vector production, and quality control [4] - Fortrea is a global provider of clinical development solutions, partnering with biopharmaceutical and biotechnology companies to drive healthcare innovation across various therapeutic areas, leveraging three decades of experience [6] Collaboration Details - The partnership aims to create synchronized solutions that de-risk programs, streamline planning, and optimize cost-efficiency throughout the development lifecycle, addressing over 4,400 gene, cell, and RNA therapies currently in development [2][3] - By combining Fortrea's clinical reach with SCTbio's manufacturing expertise, the collaboration seeks to enhance protocol design, supply chain resilience, and the delivery of therapies globally [3] - The collaboration will align clinical trial logistics with GMP manufacturing readiness, ensuring synchronized planning and execution for cell and gene therapy programs [3]